LEQEMBI

all catalysts(0)

nothing on the calendar yet

News(10)

• Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
  With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.
  biospace · 2mo ago
• Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
  Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
  biopharma_dive · 2mo ago
• Leqembi records best quarter since launch as Biogen raises underlying guidance
  Leqembi, the anti-amyloid Alzheimer’s drug from Eisai and Biogen, recorded $184 million in global sales in the second quarter, Biogen said Wednesday morning. It's the best showing for Leqembi since…
  endpoints · 2mo ago
• Biogen counts on drugs from Apellis deal to patch Leqembi's slow sales
  It’s no secret that sales of Leqembi have been disappointing. First approved in 2023, the Alzheimer’s drug from Eisai and Biogen launched shortly after Chris Viehbacher took the reins as Biogen CEO…
  endpoints · 2mo ago
• Erasca's $550M offering; Summit sells an antibiotic
  Plus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public offering came after it shared a small ...
  endpoints · 2mo ago
• STAT+: Akero team, backed by Fairmount, launches new immunology company
  FDA approves injectable Leqembi, another post-Makary reversal, and other biotech news from The Readout
  stat · 2mo ago
• Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs
  The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.
  biopharma_dive · 2mo ago
• STAT+: Medicare’s miss on Alzheimer’s drug spending
  Far fewer seniors than expected are taking costly Alzheimer's drugs.
  stat · 4mo ago
• STAT+: Pharmalittle: We’re reading about Medicare and Alzheimer’s drugs, estrogen patch shortages, and more
  People on Medicare are not getting the recently approved Alzheimer’s medications nearly as much as federal officials anticipated
  stat · 4mo ago
• STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs
  Adoption has been slow with new Alzheimer’s drugs because the treatments are complicated to administer and the benefits are uncertain.
  stat · 4mo ago